Design the campaign around the scientific decision—not the software.
Qualify the target, choose a transparent screening funnel, run real structure-based computation, persist post-docking ADMET/novelty/synthesis evidence, inspect the evidence and continue the same candidates into a persistent Discovery Programme. Docking and model/search outputs remain computational or retrieved evidence; experiments and qualified human review remain the decision gate.
Plan Discovery Campaign
Core readiness contract
A custom target is not made “ready” by entering a PDB ID. Required structural and protocol checks remain explicit.
Advanced physics options
Campaign running
Loading campaign state…
Current scientific activity
Quantitative progress appears only when the executor reports real counts/percentages. Other stages use discrete states.
Campaign artifacts
Downloads appear when the relevant stage has produced an artifact. Integrated CSV/JSON and the verified PDF are derived from persisted evidence, not browser state.
Future downstream capability
It may become appropriate later for an experimentally established congeneric analogue series. It is not shown as “complete” during screening.
Shortlist ready for persistent scientific review.
The final candidates remain computational hypotheses. BayesPharma preserves docking and post-docking evidence in the persistent Programme ledger so the next work happens on Candidate Passports rather than in an isolated result table.
Human/CRO-review shortlist
Structure-first cards expose the ranking channels without pretending one score proves binding.
Research-use computational decision support. Target qualification is target-specific. Optional MD/MM-GBSA is executed only when scientifically qualified. ADMET/safety predictions, PubChem identity retrieval and AiZynthFinder routes do not replace experimental or legal validation.